Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD)…
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
Opus Genetics, Inc. – Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data…
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…
Phase 3 Trial Success: New Presbyopia Eye Drop Shows 27% Vision Improvement
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety…
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Opus Genetics, Inc. Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near…